25 March 2023 in npj Parkinson's Disease
Dopamine dyshomeostasis has been acknowledged among the determinants of nigrostriatal neuron degeneration in Parkinson’s disease (PD). Several studies in experimental models and postmortem PD patients underlined increasing levels of the dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is highly reactive towards proteins. DOPAL has been shown to covalently modify the presynaptic protein αSynuclein (αSyn), whose misfolding and aggregation represent a major trait of PD pathology, triggering αSyn oligomerization in dopaminergic neurons. Here, we demonstrated that DOPAL elicits αSyn accumulation and hampers αSyn clearance in primary neurons. DOPAL-induced αSyn buildup lessens neuronal resilience, compromises synaptic integrity, and overwhelms protein quality control pathways in neurites. The progressive decline of neuronal homeostasis further leads to dopaminergic neuron loss and motor impairment, as showed in in vivo models. Finally, we developed a specific antibody which detected increased DOPAL-modified αSyn in human striatal tissues from idiopathic PD patients, corroborating the translational relevance of αSyn-DOPAL interplay in PD neurodegeneration.
19 July 2024 in Chemistry – A European Journal
A β‐glucosyl sterol probe bearing a terminal alkyne moiety for fluorescent tagging enables the investigation of the neuronal and intracellular localization of this class of compounds involved in neurodegenerative diseases. The compound showed localization in the neuronal cells, with marked differences in the uptake and metabolism leading to enhanced persistence with respect to the un‐glycosylated sterol analogue. In addition, a different impact was observed towards lysosomes, with the simple sterol probe showing the enlargement of the lysosome structures, while the β‐glucosyl sterol was less capable to alter the morphology of this specific organelle.
24 March 2026 in Research Square
Background Glucosylated-sterols can be synthetized endogenously, absorbed through the diet or derive from bacterial infection. Their clinical relevance is currently underestimated, even though their imbalance has been associated with higher risk of undergoing neurodegeneration throughout life. We studied the detrimental effects elicited by dietary consumption of plant-derived β-sitosterol β-D-glucoside (BSSG), known to be associated with the occurrence of ALS-PDC, to decipher its possible mode of action. Methods Zebrafish larvae and adults, as well as mice, were treated with BSSG dissolved directly in the water or through customized food pellet, respectively. Being the first target tissue identified, morphological and functional characterization of the intestine were performed, together with transcriptional analysis and sequencing of gut microbiota. Ex vivo analysis of zebrafish gut contractility was applied to assess intestinal neuromuscular response. Mutant and transgenic zebrafish lines were used to explore a possible BSSG mechanism of action. Results BSSG caused intestinal inflammation in both zebrafish and mouse models. This previously unknown effect was evidenced by altered gut dysmotility and inflammatory response. Transcriptomic analyses revealed increased expression of inflammation-related genes in the intestine of both zebrafish and mice, while preliminary gut microbiota analyses suggested the onset of dysbiosis. Transgenic and mutant zebrafish lines depleted of genes involved in glucocorticoids synthesis and activity evidenced that BSSG likely interacts with the glucocorticoid receptor, potentially affecting its canonical anti-inflammatory activity. Conclusions We discovered a new set of pathways altered by dietary uptake of BSSG. This molecule introduced in the organism initially determines gut inflammation, altering intestinal morphology and functionality, and possibly leads to neurodegeneration through disruption of the well-known gut-brain axis.